UNITED LAB secures dual FDA IND approvals for UBT48128 oral GLP-1 agonist targeting obesity and type 2 diabetes

Bulletin Express08-11

Hong Kong-listed The United Laboratories International Holdings Limited (UNITED LAB) has obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its self-developed UBT48128 Tablets, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The approvals cover two indications—overweight or obesity (IND 182060) and type 2 diabetes (IND 182061).

Preclinical studies in multiple animal models showed that UBT48128 significantly lowered body weight and blood-glucose levels and delivered weight-loss efficacy exceeding that of currently marketed GLP-1 products, according to the company. The compound promotes insulin secretion while regulating appetite and energy metabolism, supporting its potential therapeutic profile in chronic metabolic diseases.

UBT48128 was developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly owned subsidiary of UNITED LAB. The group stated that advancing this program aligns with its strategy to expand its biopharmaceutical pipeline focused on chronic disease treatments, aiming to enhance long-term competitiveness and shareholder value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140821468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140821468","market":"hk","top_or_hot":-1,"title":"UNITED LAB secures dual FDA IND approvals for UBT48128 oral GLP-1 agonist targeting obesity and type 2 diabetes","media":"Bulletin Express","content":"<p>Hong Kong-listed The United Laboratories International Holdings Limited (UNITED LAB) has obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its self-developed UBT48128 Tablets, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The approvals cover two indications—overweight or obesity (IND 182060) and type 2 diabetes (IND 182061).</p>\n<p>Preclinical studies in multiple animal models showed that UBT48128 significantly lowered body weight and blood-glucose levels and delivered weight-loss efficacy exceeding that of currently marketed GLP-1 products, according to the company. The compound promotes insulin secretion while regulating appetite and energy metabolism, supporting its potential therapeutic profile in chronic metabolic diseases.</p>\n<p>UBT48128 was developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly owned subsidiary of UNITED LAB. The group stated that advancing this program aligns with its strategy to expand its biopharmaceutical pipeline focused on chronic disease treatments, aiming to enhance long-term competitiveness and shareholder value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB secures dual FDA IND approvals for UBT48128 oral GLP-1 agonist targeting obesity and type 2 diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB secures dual FDA IND approvals for UBT48128 oral GLP-1 agonist targeting obesity and type 2 diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-11 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed The United Laboratories International Holdings Limited (UNITED LAB) has obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its self-developed UBT48128 Tablets, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The approvals cover two indications—overweight or obesity (IND 182060) and type 2 diabetes (IND 182061).</p>\n<p>Preclinical studies in multiple animal models showed that UBT48128 significantly lowered body weight and blood-glucose levels and delivered weight-loss efficacy exceeding that of currently marketed GLP-1 products, according to the company. The compound promotes insulin secretion while regulating appetite and energy metabolism, supporting its potential therapeutic profile in chronic metabolic diseases.</p>\n<p>UBT48128 was developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly owned subsidiary of UNITED LAB. The group stated that advancing this program aligns with its strategy to expand its biopharmaceutical pipeline focused on chronic disease treatments, aiming to enhance long-term competitiveness and shareholder value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1140821468","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140821468","pubTimestamp":1786443808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed The United Laboratories International Holdings Limited (UNITED LAB) has obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联合制药获得针对肥胖和 2 型糖尿病的 UBT48128 口服 GLP-1 激动剂双重 FDA IND 批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Hong Kong-listed The United Laboratories International Holdings Limited (UNITED LAB) has obtained Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for its self-developed UBT48128 Tablets, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The approvals cover two indications—overweight or obesity (IND 182060) and type 2 diabetes (IND 182061).\nPreclinical studies in multiple animal models showed that UBT48128 significantly lowered body weight and blood-glucose levels and delivered weight-loss efficacy exceeding that of currently marketed GLP-1 products, according to the company. The compound promotes insulin secretion while regulating appetite and energy metabolism, supporting its potential therapeutic profile in chronic metabolic diseases.\nUBT48128 was developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly owned subsidiary of UNITED LAB. The group stated that advancing this program aligns with its strategy to expand its biopharmaceutical pipeline focused on chronic disease treatments, aiming to enhance long-term competitiveness and shareholder value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140821468","isCrawlerRequest":true}